TARGET AUDIENCE
This activity is intended for medical oncologists, radiation oncologists, nurses and other healthcare providers involved in the treatment of hematologic cancers.

OVERVIEW OF ACTIVITY
The clinical management of myelodysplastic syndromes remains a challenge from both a diagnostic and treatment standpoint, despite recent gains made in the understanding of this heterogeneous disease. Determining which treatment approach is most appropriate for a given patient requires careful consideration of patient-specific characteristics, physician expertise and available health system resources. To bridge the gap between research and patient care, this issue of Myelodysplastic Syndromes Update features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.

LEARNING OBJECTIVES
• Recognize the key cancer-defining features of MDS, and counsel patients accordingly regarding their prognosis, treatment goals and options.
• Appraise the role of molecular testing for MDS to facilitate diagnosis, prognostication and treatment decision-making.
• Formulate a treatment algorithm for patients with lower- and higher-risk MDS, considering patient- and disease-related factors, including cytogenetic abnormalities.
• Consider the available efficacy and safety data with the use of lenalidomide in patients with low- to intermediate-risk MDS with and without del(5q), and identify patients with MDS appropriate for this treatment.
• Evaluate the potential advantages of orally administered hypomethylating agents compared to standard parenteral administration of these drugs.
•Ascertain the utility of novel agents, such as luspatercept, in the management of anemia in patients with MDS, and consider its future role in clinical management.
• Recall promising investigational agents (eg, anti-PD-1/anti-PD-L1 monoclonal antibodies, venetoclax, IDH1/2 inhibitors) and combination strategies, and counsel appropriately selected patients regarding clinical trial enrollment.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/MDSU117/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest
resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

**FACULTY** — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

**Mikkael A Sekeres, MD, MS**  
Professor of Medicine  
Vice Chair for Clinical Research  
Director, Leukemia Program  
Professor of Medicine  
Cleveland Clinic  
Taussig Cancer Institute  
Cleveland, Ohio

**Advisory Committee:** Celgene Corporation, Daiichi Sankyo Inc.

**Steven D Gore, MD**  
Professor of Internal Medicine (Hematology)  
Yale Cancer Center  
Director, Hematologic Malignancies  
New Haven, Connecticut

**Advisory Committee and Consulting Agreement:** Celgene Corporation; **Contracted Research:** Celgene Corporation, Genentech BioOncology.


**RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS** — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Celgene Corporation.

**Hardware/Software Requirements:**  
A high-speed Internet connection  
A monitor set to 1280 x 1024 pixels or more  
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later  
Adobe Flash Player 10.2 plug-in or later  
Adobe Acrobat Reader  
(Optional) Sound card and speakers for audio

**Last review date:** August 2017  
**Expiration date:** August 2018


Garcia-Manero G et al. A Phase II study evaluating the combination of nivolumab (nivo) or ipilimumab (ipi) with azacitidine in pts with previously treated or untreated myelodysplastic syndromes (MDS). Proc ASH 2016;Abstract 344.


List A et al. Combined treatment with lenalidomide (LEN) and epoetin alfa (EA) is superior to lenalidomide alone in patients with erythropoietin (epo)-refractory, lower risk (LR) non-deletion 5q [del(5q)] myelodysplastic syndrome (MDS): Results of the E2905 Intergroup study—An ECOG-ACRIN Cancer Research Group study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health. Proc ASH 2016;Abstract 223.


Saiki R et al. NGS-based copy number analysis in 1,185 patients with myeloid neoplasms. *Proc ASH* 2016;Abstract 955.


Van de Loosdrecht A et al. Lenalidomide with or without erythropoietin and granulocyte-colony stimulating factor shows efficacy in patients with low and intermediate-1 risk myelodysplastic syndrome with or without del 5q, refractory or unlikely to respond to erythropoietin. Results of a HOVON89 Phase II randomized multicenter study. (EudraCT 2008-002195-10). *Proc ASH* 2016;Abstract 224.